Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor.

about

Etirinotecan pegol for the treatment of breast cancer.Synthesis of a peptide-universal nucleotide antigen: towards next-generation antibodies to detect topoisomerase I-DNA covalent complexes.

P2860

Q38735361-8C30328A-FF35-4A20-B020-AFC6E5940E4D Q42072372-3D25EB16-9F95-4692-B640-2D7B4EDBDC06

P2860

Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor.

Item

http://www.wikidata.org/entity/Q38180311

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor.

@en

type

Item

label

Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor.

@en

prefLabel

Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor.

@en

P1476

Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor.

@en

P2093

Carlos Alemany

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

PEGylation, successful approach to drug delivery

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.

A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.

P2888

s11912-013-0367-8

P304

367

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11912-013-0367-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1050691290

http://www.w3.org/2001/XMLSchema#string

P698

24445499

http://www.w3.org/2001/XMLSchema#string

Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor.

about

P2860

P2860

Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698